The role of Capon in multiple myeloma

Capon is a ligand protein of nitric oxide synthase 1. Recently, studies have shown that Capon is involved in the development of tumors. It is independent of the regulation of nitric oxide synthase 1 in this process. At the same time, studies have found that nitric oxide synthase 1 is expressed in mu...

Full description

Saved in:
Bibliographic Details
Main Authors: Yaodong Shen, Haiyan Liu, Siyu Gu, Ziwei Wei, Hong Liu
Format: Article
Language:English
Published: SAGE Publishing 2017-06-01
Series:Tumor Biology
Online Access:https://doi.org/10.1177/1010428317713674
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849710656946700288
author Yaodong Shen
Haiyan Liu
Siyu Gu
Ziwei Wei
Hong Liu
author_facet Yaodong Shen
Haiyan Liu
Siyu Gu
Ziwei Wei
Hong Liu
author_sort Yaodong Shen
collection DOAJ
description Capon is a ligand protein of nitric oxide synthase 1. Recently, studies have shown that Capon is involved in the development of tumors. It is independent of the regulation of nitric oxide synthase 1 in this process. At the same time, studies have found that nitric oxide synthase 1 is expressed in multiple myeloma, but its role in the development and progression of myeloma remains unclear. In this study, we found that there was a different expression of Capon between the normal multiple myeloma cells and the adherent multiple myeloma cells. In the process of myeloma cell proliferation, the reduced expression of Capon reduces the arrest of the cell cycle in the G1 phase and promotes the proliferation of myeloma cells. Cell adhesion–mediated drug resistance is one of the most important factors, which affect the chemotherapy effect of multiple myeloma. If the expression of Capon is decreased, myeloma cells are adhered to fibronectin or bone marrow stromal cells (bone marrow mesenchymal stem cells). In addition, the sensitivity of the cell line to chemotherapeutic agents was reduced after silencing Capon in the myeloma cell line which was adhered to bone marrow mesenchymal stem cells. We also found that reduced expression of Capon resulted in the activation of the AKT signaling pathway. In conclusion, these results may be helpful in studying the role of Capon in multiple myeloma.
format Article
id doaj-art-4447cbbaee6f417c8b6652c1ca91bdc6
institution DOAJ
issn 1423-0380
language English
publishDate 2017-06-01
publisher SAGE Publishing
record_format Article
series Tumor Biology
spelling doaj-art-4447cbbaee6f417c8b6652c1ca91bdc62025-08-20T03:14:50ZengSAGE PublishingTumor Biology1423-03802017-06-013910.1177/1010428317713674The role of Capon in multiple myelomaYaodong Shen0Haiyan Liu1Siyu Gu2Ziwei Wei3Hong Liu4Department of Hematology, Affiliated Hospital of Nantong University, Nantong University, Nantong, P.R. ChinaDepartment of Hematology, Affiliated Hospital of Nantong University, Nantong University, Nantong, P.R. ChinaDepartment of Hematology, Affiliated Hospital of Nantong University, Nantong University, Nantong, P.R. ChinaNantong University, Nantong, P.R. ChinaDepartment of Hematology, Affiliated Hospital of Nantong University, Nantong University, Nantong, P.R. ChinaCapon is a ligand protein of nitric oxide synthase 1. Recently, studies have shown that Capon is involved in the development of tumors. It is independent of the regulation of nitric oxide synthase 1 in this process. At the same time, studies have found that nitric oxide synthase 1 is expressed in multiple myeloma, but its role in the development and progression of myeloma remains unclear. In this study, we found that there was a different expression of Capon between the normal multiple myeloma cells and the adherent multiple myeloma cells. In the process of myeloma cell proliferation, the reduced expression of Capon reduces the arrest of the cell cycle in the G1 phase and promotes the proliferation of myeloma cells. Cell adhesion–mediated drug resistance is one of the most important factors, which affect the chemotherapy effect of multiple myeloma. If the expression of Capon is decreased, myeloma cells are adhered to fibronectin or bone marrow stromal cells (bone marrow mesenchymal stem cells). In addition, the sensitivity of the cell line to chemotherapeutic agents was reduced after silencing Capon in the myeloma cell line which was adhered to bone marrow mesenchymal stem cells. We also found that reduced expression of Capon resulted in the activation of the AKT signaling pathway. In conclusion, these results may be helpful in studying the role of Capon in multiple myeloma.https://doi.org/10.1177/1010428317713674
spellingShingle Yaodong Shen
Haiyan Liu
Siyu Gu
Ziwei Wei
Hong Liu
The role of Capon in multiple myeloma
Tumor Biology
title The role of Capon in multiple myeloma
title_full The role of Capon in multiple myeloma
title_fullStr The role of Capon in multiple myeloma
title_full_unstemmed The role of Capon in multiple myeloma
title_short The role of Capon in multiple myeloma
title_sort role of capon in multiple myeloma
url https://doi.org/10.1177/1010428317713674
work_keys_str_mv AT yaodongshen theroleofcaponinmultiplemyeloma
AT haiyanliu theroleofcaponinmultiplemyeloma
AT siyugu theroleofcaponinmultiplemyeloma
AT ziweiwei theroleofcaponinmultiplemyeloma
AT hongliu theroleofcaponinmultiplemyeloma
AT yaodongshen roleofcaponinmultiplemyeloma
AT haiyanliu roleofcaponinmultiplemyeloma
AT siyugu roleofcaponinmultiplemyeloma
AT ziweiwei roleofcaponinmultiplemyeloma
AT hongliu roleofcaponinmultiplemyeloma